Investor Alert

Vertex Pharmaceuticals Inc.



After Hours

 --Quotes are delayed by 20 min

Jul 10, 2020, 7:53 p.m.





-1.45 -0.49%


Volume 46,838

Quotes are delayed by 20 min


Previous close

$ 295.40

$ 294.45


-0.95 -0.32%

Day low

Day high




52 week low

52 week high




Annual Financials for Vertex Pharmaceuticals Inc.

Fiscal year is January-December. All values USD millions. 20152016201720182019 5-year trend
Sales/Revenue 1.03B1.7B2.49B3.05B4.13B
Cost of Goods Sold (COGS) incl. D&A 124.51M210.46M275.12M409.54M547.76M
COGS excluding D&A 62.17M149.06M213.72M337.12M440.82M
Depreciation & Amortization Expense 62.34M61.4M61.4M72.42M106.94M
Depreciation 62.34M61.4M61.4M72.42M106.94M
Amortization of Intangibles -----
Gross Income 907.82M1.49B2.21B2.64B3.58B
20152016201720182019 5-year trend
SG&A Expense 1.37B1.48B1.82B1.97B2.41B
Research & Development 995.92M1.05B1.32B1.42B1.75B
Other SG&A 376.58M432.83M490.98M557.62M658.5M
Other Operating Expense -----
Unusual Expense 2.21M1.26M288.79M28.19M(123.2M)
EBIT after Unusual Expense (2.21M)9.94M109.14M637.03M1.29B
Non Operating Income/Expense (6.72M)4.13M(67.28M)(2.67M)97.06M
Non-Operating Interest Income ----63.68M
Equity in Affiliates (Pretax) -----
Interest Expense 84.21M81.43M57.55M34.12M58.5M
Gross Interest Expense 84.21M81.43M57.55M34.12M58.5M
Interest Capitalized -----
Pretax Income (557.8M)(67.37M)(15.69M)600.24M1.39B
Income Tax 30.38M16.67M(107.32M)(1.49B)218.11M
Income Tax - Current Domestic 29.25M(1.99M)16.58M9.79M13.53M
Income Tax - Current Foreign 831,0001.79M3.58M15.6M37.19M
Income Tax - Deferred Domestic 653,00020.22M(124.26M)(1.15B)192.18M
Income Tax - Deferred Foreign (355,000)(3.36M)(3.22M)(364.92M)(24.8M)
Income Tax Credits -----
Equity in Affiliates -----
Other After Tax Income (Expense) --(293,000)(501,000)-
Consolidated Net Income (588.18M)(84.03M)91.34M2.09B1.18B
Minority Interest Expense (31.85M)28.02M(171.85M)(9.79M)-
Net Income (556.33M)(112.05M)263.19M2.1B1.18B
Extraordinaries & Discontinued Operations -----
Extra Items & Gain/Loss Sale Of Assets -----
Cumulative Effect - Accounting Chg -----
Discontinued Operations -----
Net Income After Extraordinaries (556.33M)(112.05M)263.19M2.1B1.18B
Preferred Dividends -----
Net Income Available to Common (556.33M)(112.05M)263.19M2.1B1.18B
EPS (Basic) (2.31)(0.46)
Basic Shares Outstanding 241.31M244.69M248.86M254.29M256.73M
EPS (Diluted) (2.31)(0.46)
Diluted Shares Outstanding 241.31M244.69M253.23M259.19M260.67M
EBITDA (402.33M)72.6M459.33M737.64M1.28B
Link to MarketWatch's Slice.